GlassScriptPhysician profile
Jenna L Hoffman
NPI 1164894242
$1,624.60
in general payments reported to CMS, 2019-2025
29 companies · $99.00 in 2025
The $99.00 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $465 · 2023: $665 · 2024: $255 · 2025: $99.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605 · Education: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.21 |
| Education | $413.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $240.43 | 2021-2025 | Rybrevant |
| Seagen INC. | $223.65 | 2022-2023 | Tukysa |
| Incyte Corporation | $154.20 | 2022-2023 | Jakafi, Pemazyre, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $115.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $102.82 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $90.95 | 2022-2024 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $87.27 | 2022-2024 | Keytruda |
| Eisai INC. | $75.78 | 2023-2024 | |
| Pfizer INC. | $67.07 | 2021-2024 | |
| Daiichi Sankyo INC. | $60.44 | 2022-2023 | Enhertu |
| Beigene USA, INC. | $49.98 | 2023-2024 | Brukinsa |
| Gilead Sciences, INC. | $42.91 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $33.03 | 2023 | Opdivo |
| Lilly USA, LLC | $25.21 | 2021-2022 | |
| Myovant Sciences INC. | $23.93 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $23.32 | 2023 | Empaveli |
| Pharmaessentia USA Corporation | $19.17 | 2024 | Besremi |
| Sumitomo Pharma America, INC. | $18.01 | 2024 | Orgovyx |
| Servier Pharmaceuticals LLC | $17.80 | 2024 | |
| Rigel Pharmaceuticals, INC. | $17.61 | 2022 | |
| Aveo Pharmaceuticals, INC. | $17.31 | 2022 | |
| Array Biopharma INC | $15.98 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.63 | 2021 | |
| Taiho Oncology, INC. | $15.57 | 2023 | |
| Mirati Therapeutics, INC. | $15.26 | 2023 | Krazati |
| Deciphera Pharmaceuticals INC. | $14.43 | 2022 | |
| Genentech USA, INC. | $14.27 | 2023 | Lunsumio, Polivy |
| Astellas Pharma US INC | $13.90 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.